$3.58
+0.05 (+1.42%)
Open$3.68
Previous Close$3.53
Day High$3.78
Day Low$3.47
52W High$106.20
52W Low$3.51
Volume—
Avg Volume149.3K
Market Cap2.31M
P/E Ratio—
EPS$-1,011.67
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+1,143.9% upside
Current
$3.58
$3.58
Target
$44.53
$44.53
$37.12
$44.53 avg
$63.68
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.28M | 1.20M | 1.36M |
| Net Income | 141.5K | 105.1K | 144.5K |
| Profit Margin | 11.1% | 8.8% | 10.6% |
| EBITDA | 291.4K | 241.4K | 275.9K |
| Free Cash Flow | 83.4K | 101.2K | 72.7K |
| Rev Growth | +11.3% | +13.4% | -9.5% |
| Debt/Equity | 0.31 | 0.28 | 0.30 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 35.2 | 28.41B |